REFERENCES – TOWN HALL 91 – 10-22-2023


https://www.nature.com/articles/s41598-023-44989-5

A randomized controlled trial published in *The New England Journal of Medicine* showed that treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery than placebo among outpatients with COVID-19.


A *JAMA Network Open* study demonstrated that high-flow nasal oxygen and noninvasive ventilation appear not to be aerosol-generating procedures.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810485?guestAccessKey=7c3b5876-0b0d-4e3c-9934-3dc5e8d276f9&utm_source=silverchair&utm_medium=email&utm_campaign=jama_network&utm_content=covid_weekly_highlights&adv=001602730367

A large *JAMA Network Open* retrospective cohort study found that COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders.


A *JAMA Internal Medicine* study of US veterans found that COVID-19 survivors had no clinically significant excess hazard of death greater than comparators among those who survived at least 6 months after infection.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808237?guestAccessKey=f00cadc8-f47b-4832-9a0e-4b110f8b089&utm_source=silverchair&utm_medium=email&utm_campaign=jama_network&utm_content=covid_weekly_highlights&adv=001602730367

A *JAMA* study found that that long-term support for family members of ICU patients with COVID-19 ARDS should be the same as for relatives of patients with other causes of ARDS.

https://jamanetwork.com/journals/jama/fullarticle/2809191

A *Lancet Public Health* paper provided a retrospective assessment of COVID surveillance systems used in England during the pandemic, concluding that deploying a suite of monitoring systems is optimal.

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00219-0/fulltext

Another *Lancet* paper reported on the comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab for preventing severe COVID-19 outcomes in non-hospitalized high-risk patients during Omicron waves, finding approximately equivalent outcomes for both.

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00160-6/fulltext

An opinion piece in *The Journal of Infectious Diseases* presents evidence that so-called ‘hybrid immunity’ (i.e., vaccination plus infection) produces more robust immunity than either alone.

REFERENCES – TOWN HALL 91 – 10-22-2023 (CONTINUED)

A paper in *Clinical Infectious Diseases* found that, in a highly immune adult population, median SARS-CoV-2 viral loads peaked around the fourth day of symptoms and that Influenza A viral loads peaked soon after symptom onset.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad582/7285011?searchresult=1

A short *Clinical Infectious Diseases* opinion piece written by a fellow in Infectious Diseases describes his grieving process during the pandemic in part stimulated by his struggles with close family members who routinely reported their anti-science and conspiracy theories about COVID.


A paper in *Infection Control and Hospital Epidemiology* found that an immediate, substantial, and sustained increase of healthcare-associated respiratory viral infections occurred after the institution discontinued universal masking.


The U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, adjuvanted to include the 2023-2024 formula for anyone 12 years of age and older.


The NIAID is beginning a clinical trial of a “Universal” influenza vaccine.